Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 6;28(1):71–83. doi: 10.1158/1078-0432.CCR-21-0845

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 5. A, Spider plot of tumor size change from baseline over time by dose and tumor type (RECIST). B, Patient receiving ivuxolimab at 10 mg/kg received radiotherapy to a nontarget lesion after 8 cycles and subsequently developed vitiligo. The patient's status was SD after 8 cycles, but by cycle 14 (day 212) of ivuxolimab, the patient achieved a durable PR lasting until cycle 31 (day 462). — A, Spider plot of tumor size change from baseline over time by dose and tumor type (RECIST). B, Patient receiving ivuxolimab at 10 mg/kg received radiotherapy to a nontarget lesion after 8 cycles and subsequently developed vitiligo. The patient's status was SD after 8 cycles, but by cycle 14 (day 212) of ivuxolimab, the patient achieved a durable PR lasting until cycle 31 (day 462).